Checkpoint molecules in cancer immunotherapy

Discovery Immunology journal

Led by Dr Seth Coffelt (University of Glasgow) and Professor Awen Gallimore (Cardiff University)

The T cell response can be inhibited by checkpoint molecules that normally act to prevent unwanted inflammation. These molecules are subverted by tumours to enable their growth.

In the first Special Collection from the BSI's newest journal Discovery Immunology, Dr Seth Coffelt and Professor Awen Gallimore highlight articles describing new mechanisms by which these molecules function and their potential therapeutic uses.

All articles are Open Access. 

Figure depicting the variation in cell marker and transcription factor expression in ILC1s in mice and humans

REVIEW

Twenty-One Flavors of Type 1 Innate Lymphoid Cells with PD-1 (Programmed Cell Death-1 Receptor) Sprinkles

Katie J Smith, Giuseppe Sciumè, Shoba Amarnath

Figure from Migration of stem-like CD8 T cells between tissue microenvironments underpins successful anti-tumour immune responses

REVIEW

Migration of stem-like CD8 T cells between tissue microenvironments underpins successful anti-tumour immune responses

Bethany C Kennedy, Isaac Dean, David R Withers

Figure from The effect of abatacept on T-cell activation is not long-lived in vivo

RESEARCH ARTICLE

The effect of abatacept on T-cell activation is not long-lived in vivo

Larissa C da Rosa, Hannah E Scales, Robert A Benson, James M Brewer, Iain B McInnes, Paul Garside

Figure from Immunotherapy in the context of immune-specialized environment of brain metastases

REVIEW

Immunotherapy in the context of immune-specialized environment of brain metastases

Fiona James, Mihaela Lorger